Find in Library

Abstract The liquid biopsy concept has been introduced for circulating tumor cells more than 10 years ago (Pantel & Alix‐Panabieres, 2010) and rapidly extended to cell‐free DNA released from tumor cells (ctDNA; Lo et al, 2021) and other tumor‐derived products such as circulating cell‐free RNA (noncoding and messenger RNA), extracellular vesicles, or tumor‐educated platelets (Alix‐Panabières & Pantel, 2021). In this issue of EMBO Molecular Medicine, the report of Sauer et al (2022) demonstrates the feasibility of longitudinal monitoring of disease burden and response using ctDNA from dried blood spots in xenograft models.